Cleveland Clinic
Cleveland, Ohio, 44195, United States
NCT Number: NCT00231231
The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease during peri-approval/initial commercialization in relation to the outcomes of the Sapphire Clinical Trial. The devices to be utilized are the Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW).
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
Cleveland, Ohio, 44195, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
· congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%
<!-- -->
· Stenosis >50%: PSV>130 cm/sec; EDV <135 cm/sec
· Stenosis >80%: PSV>220 cm/sec; EDV <135 cm/sec
· PSV ICA/PSV CCA ratio 4.0
Exclusion criteria
Time frame: 30 day
Cordis US Corp.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00597883
Arterial Occlusive Diseases, Brain Diseases
New York, United States
View Trial DetailsNCT02163408
Brain Diseases, Cardiovascular Diseases
Los Angeles, California, United States
View Trial DetailsNCT00587717
Brain Diseases, Cardiovascular Diseases
View Trial DetailsNCT02126982
Acute Coronary Syndrome, Arrhythmias, Cardiac
Ioannina, Epirus, Greece
View Trial Details